UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Tesco is the UK’s biggest grocer again — and its FY26 results explain exactly why Aldi and Lidl should be paying attention
Read More Pharma Industry News FDA doubles down on Palvella’s QTORIN rapamycin as Phase 3 SELVA trial exceeds enrollment Find out how the FDA’s renewed orphan grant is accelerating Palvella Therapeutics’ Phase 3 QTORIN trial toward potential approval in rare disease care. bySoujanya RaviOctober 13, 2025